Centogene N.V. Forecasts Stronger Growth in 2024
Company Announcements

Centogene N.V. Forecasts Stronger Growth in 2024

Centogene N.V. (CNTG) has released an update.

Centogene N.V. reported a modest 2% increase in total revenue for FY2023, reaching €48.5 million, and anticipates a stronger performance with projected growth of 10-15% in 2024. The company has fortified its cash position by securing approximately $20 million, partly through expanding its partnership with Lifera. Despite a net loss increase and a dip in Pharma segment revenues, Centogene remains optimistic with strategic collaborations and a robust diagnostics demand paving the way for future profitability.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene NV Announces Nasdaq Delisting
TheFlyCentogene receives delisting notice from Nasdaq
TheFlyCentogene publishes ROPAD study data on Parkinson’s disease in Brain
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App